China's CanSino COVID-19 vaccine gets green light to start phase 3 trials

Beijing, China's CanSino Biologics Inc. has got green light to continue phase-3 trials of its Covid-19 vaccine with the support of findings of an independent data monitoring committee, said media reports.

The independent committee "found the drugmaker's Covid-19 vaccine met its pre-specified primary safety and efficacy targets under an interim analysis of phase-3 trial data," the report said.

No adverse events related to the vaccine had occurred, according to the Xinhua news agency.

The vaccine candidate, referred to as Ad5-nCoV, is developed by CanSino Biologics Inc. and the Academy of Military Sciences in China.

CanSino was approved to conduct phase-3 clinical trials in some countries in Europe and Asia, Wu Yuanbin, an official with China's Ministry of Science and Technology, said in September last year.


SEE ALSO:
Warburg Pincus-backed Home First Finance Company IPO lists at 19% premium over the issue price
INTERVIEW: Google and Facebook ahoy! India’s Principal Economic Advisor says the real monopoly to be worried about is in search, internet and social media
Budget 2021-22 prioritises Gaganyaan, India’s human spaceflight mission, over all others — here’s why